Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis With Significant Comorbidities in Very High Risk Subjects Who Need Aortic Valve Replacement

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2013 by Medtronic Cardiovascular
Sponsor:
Information provided by (Responsible Party):
Medtronic Cardiovascular
ClinicalTrials.gov Identifier:
NCT01675440
First received: August 22, 2012
Last updated: October 18, 2013
Last verified: October 2013

August 22, 2012
October 18, 2013
August 2012
August 2017   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01675440 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis With Significant Comorbidities in Very High Risk Subjects Who Need Aortic Valve Replacement
Medtronic CoreValve® U.S. Expanded Use Study

The primary objective of the study is to evaluate the safety and effectiveness of the Medtronic CoreValve® System (MCS) in a subset of subjects excluded from the U.S. Extreme Risk Pivotal Trial population due to one or more additional co-morbidities, as measured by a composite of all-cause death or major stroke at 12 months, in the treatment of symptomatic severe aortic stenosis in subjects necessitating aortic valve replacement. Subjects enrolled in this study have a predicted operative mortality or serious, irreversible morbidity risk of ≥50% at 30 days associated with surgical aortic valve replacement.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Probability Sample

Subjects with symptomatic severe aortic stenosis requiring aortic valve replacement, with predicted operative mortality or serious, irreversible morbidity risk of ≥ 50% at 30 days, and at least one of the following conditions:

  • Severe (≥3-4+) mitral valve regurgitation
  • Severe (≥3-4+) tricuspid valve regurgitation
  • End stage renal disease (ESRD) requiring renal replacement therapy
  • Low gradient, low output aortic stenosis
  • Failed bioprosthetic surgical aortic valve
  • 2 or more conditions (listed above)
Severe Aortic Stenosis
Device: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
  • Severe (≥3-4+) mitral valve regurgitation
    Intervention: Device: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
  • Severe (≥3-4+) tricuspid valve regurgitation
    Intervention: Device: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
  • End stage renal disease (ESRD)
    requiring renal replacement therapy
    Intervention: Device: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
  • Low gradient, low output aortic stenosis
    Intervention: Device: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
  • 2 or more conditions
    Intervention: Device: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
  • Failed bioprosthetic surgical aortic valve
    Intervention: Device: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
550
Not Provided
August 2017   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject must have co-morbidities such that one cardiologist and two cardiac surgeons agree that medical factors preclude operation, based on a conclusion that the probability of death or serious morbidity exceeds the probability of meaningful improvement. Specifically, the predicted operative risk of death or serious, irreversible morbidity is ≥ 50% at 30 days.
  • Subjects must meet all of the criteria under at least one of the sub-groups 2a-c:

    a. Senile degenerative aortic valve stenosis and i. At least one of the following co-morbid conditions:

    1. Severe (≥3-4+) mitral valve regurgitation as measured by echocardiography
    2. Severe (≥3-4+) tricuspid valve regurgitation as measured by echocardiography
    3. End-stage renal disease requiring renal replacement therapy (Stage 5 of the KDOQI CKD Classification)

      AND

      ii. mean gradient > 40 mmHg or jet velocity greater than 4.0 m/sec by either resting or dobutamine stress echocardiogram (if the LVEF < 50%), or simultaneous pressure recordings at cardiac catheterization either resting or with dobutamine stress (if the LVEF < 50%), AND iii. an initial aortic valve area of ≤ 0.8 cm2 (or aortic valve area index ≤0.5 cm2/m2) by resting echocardiogram or simultaneous pressure recordings at cardiac catheterization

      AND/OR

      b. Low gradient, low output aortic stenosis as defined by the presence of all three of the following i. In the presence of LVEF <50%, absence of contractile reserve, a mean gradient <40mmHg AND jet velocity less than 4.0m/sec with dobutamine stress echocardiography or simultaneous pressure recordings at cardiac catheterization OR In the presence of LVEF ≥50%, a mean gradient <40mmHg AND jet velocity less than 4.0 m/sec, by echocardiography or simultaneous pressure recordings at cardiac catheterization ii. an initial aortic valve area of ≤0.8 cm2 (or aortic valve area index ≤0.5 cm2/m2) by resting echocardiogram or simultaneous pressure recordings at cardiac catheterization AND iii. radiographic evidence of severe aortic valve calcification c. Failed bioprosthetic surgical aortic valve

  • Subject is symptomatic from his/her aortic valve stenosis, as demonstrated by New York Heart Association (NYHA) Functional Class II or greater.
  • The subject or the subject's legal representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the IRB of the respective clinical site.
  • The subject and the treating physician agree that the subject will return for all required post-procedure follow-up visits.

Exclusion Criteria:

Clinical

  • Evidence of an acute myocardial infarction ≤30 days before the MCS TAVI procedure.
  • Any percutaneous coronary or peripheral interventional procedure performed within 30 days prior to the MCS TAVI procedure
  • Blood dyscrasias as defined: leukopenia (WBC <1000mm3), thrombocytopenia (platelet count <50,000 cells/mm3), history of bleeding diathesis or coagulopathy.
  • Untreated clinically significant coronary artery disease requiring revascularization.
  • Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or mechanical hemodynamic support.
  • Need for emergency surgery for any reason.
  • Severe ventricular dysfunction with left ventricular ejection fraction (LVEF) <20% as measured by resting echocardiogram.
  • Recent (within 6 months) cerebrovascular accident (CVA) or transient ischemic attack (TIA).
  • Active Gastrointestinal (GI) bleeding within the past 3 months.
  • Hypersensitivity or contraindication to aspirin, heparin, ticlopidine, clopidogrel, warfarin, nitinol, or sensitivity to contrast media which cannot be adequately pre-medicated.
  • Ongoing sepsis, including active endocarditis.
  • Subject refuses a blood transfusion.
  • Life expectancy <12 months due to associated non-cardiac co-morbid conditions.
  • Other medical, social, or psychological conditions that in the opinion of an Investigator precludes the subject from appropriate consent.
  • Severe dementia (resulting in either inability to provide informed consent for the study/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits).
  • Currently participating in an investigational drug or another device study.
  • Symptomatic carotid or vertebral artery disease.

Anatomical

  • Native aortic annulus size <18 mm or >29 mm per the baseline diagnostic imaging.
  • Pre-existing prosthetic heart valve in the any position
  • Moderate to severe mitral stenosis.
  • Mixed aortic valve disease: aortic stenosis and aortic regurgitation with predominant aortic regurgitation, (AR is moderate-severe to severe (≥3-4+))(except for failed surgical bioprothesis)
  • Hypertrophic obstructive cardiomyopathy.
  • Echocardiographic evidence of new or untreated intracardiac mass, thrombus or vegetation.
  • Severe basal septal hypertrophy with an outflow gradient.
  • Aortic root angulation (angle between plane of aortic valve annulus and horizontal plane/vertebrae) >70° (for femoral and left subclavian/axillary access) and >30° (for right subclavian/axillary access).
  • Ascending aorta that exceeds the maximum diameter for any given native aortic annulus size (see table below) Aortic Annulus Diameter Ascending Aorta Diameter 18 mm - 20 mm >34 mm 20 mm - 23 mm >40 mm 23 mm - 27 mm >43 mm 27 mm - 29 mm >43 mm
  • Congenital bicuspid or unicuspid valve verified by echocardiography.
  • Sinus of valsalva anatomy that would prevent adequate coronary perfusion.
  • Degenerated surgical bioprothesis presents with a significant concomitant perivalvular leak (between prothesis and native annulus), is not securely fixed in the native annulus, or is not structurally intact (e.g. wireform frame fracture) (ONLY FOR TAV in SAV subjects)
  • Degenerated surgical bioprothesis presents with a partially detached leaflet that in the aortic position may obstruct a coronary ostium (ONLY FOR TAV in SAV subjects)

Vascular

  • Transarterial access not able to accommodate an 18Fr sheath.
Both
Not Provided
No
Contact: Erin McDowell RS.CSTechSupport@medtronic.com
United States
 
NCT01675440
10050361DOC
Not Provided
Medtronic Cardiovascular
Medtronic Cardiovascular
Not Provided
Not Provided
Medtronic Cardiovascular
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP